Cargando…
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib (VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged during Transfection (RET) and other kinase receptors and are approved for the treatment of advanced MTC. We aim to compare t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002338/ https://www.ncbi.nlm.nih.gov/pubmed/33809722 http://dx.doi.org/10.3390/ijms22063031 |
_version_ | 1783671440317349888 |
---|---|
author | Carra, Silvia Gaudenzi, Germano Dicitore, Alessandra Saronni, Davide Cantone, Maria Celeste Plebani, Alice Ghilardi, Anna Borghi, Maria Orietta Hofland, Leo J. Persani, Luca Vitale, Giovanni |
author_facet | Carra, Silvia Gaudenzi, Germano Dicitore, Alessandra Saronni, Davide Cantone, Maria Celeste Plebani, Alice Ghilardi, Anna Borghi, Maria Orietta Hofland, Leo J. Persani, Luca Vitale, Giovanni |
author_sort | Carra, Silvia |
collection | PubMed |
description | Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib (VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged during Transfection (RET) and other kinase receptors and are approved for the treatment of advanced MTC. We aim to compare the in vitro and in vivo anti-tumor activity of VAN and CAB in MTC. The effects of VAN and CAB on viability, cell cycle, and apoptosis of TT and MZ-CRC-1 cells are evaluated in vitro using an MTT assay, DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, respectively. In vivo, the anti-angiogenic potential of VAN and CAB is evaluated in Tg(fli1a:EGFP)(y1) transgenic fluorescent zebrafish embryos by analyzing the effects on the physiological development of the sub-intestinal vein plexus and the tumor-induced angiogenesis after TT and MZ-CRC-1 xenotransplantation. VAN and CAB exert comparable effects on TT and MZ-CRC-1 viability inhibition and cell cycle perturbation, and stimulated apoptosis with a prominent effect by VAN in MZ-CRC-1 and CAB in TT cells. Regarding zebrafish, both drugs inhibit angiogenesis in a dose-dependent manner, in particular CAB shows a more potent anti-angiogenic activity than VAN. To conclude, although VAN and CAB show comparable antiproliferative effects in MTC, the anti-angiogenic activity of CAB appears to be more relevant. |
format | Online Article Text |
id | pubmed-8002338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80023382021-03-28 Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model Carra, Silvia Gaudenzi, Germano Dicitore, Alessandra Saronni, Davide Cantone, Maria Celeste Plebani, Alice Ghilardi, Anna Borghi, Maria Orietta Hofland, Leo J. Persani, Luca Vitale, Giovanni Int J Mol Sci Article Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib (VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged during Transfection (RET) and other kinase receptors and are approved for the treatment of advanced MTC. We aim to compare the in vitro and in vivo anti-tumor activity of VAN and CAB in MTC. The effects of VAN and CAB on viability, cell cycle, and apoptosis of TT and MZ-CRC-1 cells are evaluated in vitro using an MTT assay, DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, respectively. In vivo, the anti-angiogenic potential of VAN and CAB is evaluated in Tg(fli1a:EGFP)(y1) transgenic fluorescent zebrafish embryos by analyzing the effects on the physiological development of the sub-intestinal vein plexus and the tumor-induced angiogenesis after TT and MZ-CRC-1 xenotransplantation. VAN and CAB exert comparable effects on TT and MZ-CRC-1 viability inhibition and cell cycle perturbation, and stimulated apoptosis with a prominent effect by VAN in MZ-CRC-1 and CAB in TT cells. Regarding zebrafish, both drugs inhibit angiogenesis in a dose-dependent manner, in particular CAB shows a more potent anti-angiogenic activity than VAN. To conclude, although VAN and CAB show comparable antiproliferative effects in MTC, the anti-angiogenic activity of CAB appears to be more relevant. MDPI 2021-03-16 /pmc/articles/PMC8002338/ /pubmed/33809722 http://dx.doi.org/10.3390/ijms22063031 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Carra, Silvia Gaudenzi, Germano Dicitore, Alessandra Saronni, Davide Cantone, Maria Celeste Plebani, Alice Ghilardi, Anna Borghi, Maria Orietta Hofland, Leo J. Persani, Luca Vitale, Giovanni Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model |
title | Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model |
title_full | Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model |
title_fullStr | Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model |
title_full_unstemmed | Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model |
title_short | Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model |
title_sort | vandetanib versus cabozantinib in medullary thyroid carcinoma: a focus on anti-angiogenic effects in zebrafish model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002338/ https://www.ncbi.nlm.nih.gov/pubmed/33809722 http://dx.doi.org/10.3390/ijms22063031 |
work_keys_str_mv | AT carrasilvia vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT gaudenzigermano vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT dicitorealessandra vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT saronnidavide vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT cantonemariaceleste vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT plebanialice vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT ghilardianna vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT borghimariaorietta vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT hoflandleoj vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT persaniluca vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel AT vitalegiovanni vandetanibversuscabozantinibinmedullarythyroidcarcinomaafocusonantiangiogeniceffectsinzebrafishmodel |